Dr. Michael O. Ojelabi, M.D
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 186
Licensed in Illinois since 2008, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 55788 · IA license 40559 · IL license 036.121327 (first issued 2008; not renewed)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Gundersen Lutheran Medical Center La Crosse, WI
- Tomah Memorial Hospital Tomah, WI
- Crossing Rivers Health Medical Center Prairie Du Chien, WI
- Gundersen St Josephs Hospital and Clinics Hillsboro, WI
- Gundersen Boscobel Area Hospital and Clinics Boscobel, WI
Medical groups
- Gundersen Lutheran Medical Center Inc (895 clinicians)
- Gundersen Clinic LTD (418 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 186
- Services billed
- 762
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 197 | 106 |
| Established patient office or other outpatient visit, 20-29 minutes | 52 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 40 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 38 | 38 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in La Crosse, WI | 130 |
| Ondansetron Hcl Other prescribers in La Crosse, WI | 107 |
| Abiraterone Acetate | 105 |
| Dexamethasone Other prescribers in La Crosse, WI | 86 |
| Anastrozole Other prescribers in La Crosse, WI | 66 |
| Prochlorperazine Maleate Other prescribers in La Crosse, WI | 41 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in La Crosse, WI | 33 |
| Furosemide Other prescribers in La Crosse, WI | 23 |
| Mirtazapine Other prescribers in La Crosse, WI | 23 |
| Oxycodone Hcl Other prescribers in La Crosse, WI | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $26,656 in research payments for these studies, mostly to the institutions running them.
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06577441
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.